Rate My Professor Andreas Lundqvist

Andreas Lundqvist is Professor of Oncological Immunotherapy in the Department of Oncology-Pathology at Karolinska Institutet, a position he assumed on 1 February 2023. He holds a degree in chemical engineering from KTH Royal Institute of Technology obtained in 1997 and a PhD from Karolinska Institutet awarded in 2003. After completing his doctorate, Lundqvist spent six years at the U.S. National Institutes of Health, where he served as postdoctoral fellow from 2003, research fellow from 2005, and staff scientist from 2008 to 2009. Returning to Karolinska Institutet in 2009, he was appointed Assistant Professor until 2013, became Docent in 2012, and continued as Researcher until 2023. He established his research group in tumor immunology in 2009 and has supervised ten PhD students as principal supervisor. Lundqvist has taken on significant administrative roles, including Director of Doctoral Education in the Department of Oncology-Pathology from 2014 to 2023, faculty representative in the Committee for Doctoral Education since 2023, KI representative for the patient area Head, Neck, Lung, and Skin Cancer within Theme Cancer at Karolinska University Hospital since 2020, and Assistant Head of Department since 2025.

His research centers on tumor immunology and cell-based immune therapy for cancer, with a focus on mechanisms of immune escape in solid tumors. The work examines how tumors suppress immune responses, particularly involving natural killer (NK) cells and T cells, to develop improved immunotherapies and identify biomarkers for personalized treatment responses. Key projects explore NK cell infiltration and function in tumors like renal cell carcinoma, strategies to overcome immunosuppression, and synergistic therapies. Selected publications include "Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis" (Science Translational Medicine, 2024), "CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment" (Journal of Clinical Investigation, 2020), "Cancer classification using the Immunoscore: a worldwide task force" (Journal of Translational Medicine, 2012), and "Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma" (Journal for ImmunoTherapy of Cancer, 2017). His contributions have advanced insights into NK cell roles in cancer immunotherapy and mechanisms of therapy resistance.